Outlook Therapeutics, Inc. — Income Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↓-100.0% -$49K
$0
Cost of Revenue
$30K
Gross Profit
$-1M
R&D↓-62.4% -$6M
$4M
SG&A↓-27.9% -$3M
$9M
D&A↑+4.4% +$1K
$30K
Operating Income↑+37.6% +$8M
$-13M
EBITDA↑+37.7% +$8M
$-13M
Interest Expense
$626K
Interest Income
$240K
Other Income/Expense↓-106.9% -$69M
$-4M
Pretax Income↓-145.4% -$65M
$-20M
Tax Provision
$0
Net Income↓-232.7% -$40M
$-23M
Gross Margin
70.8%
Operating Margin↑+3789.0pts
-1046.2%
Net Margin↓-12315.0pts
-1338.8%
Effective Tax Rate↑+0.0pts
0.0%
ETR (Continuing Operations)↑+2.4pts
2.4%
ETR Federal Statutory↑+0.0pts
21.0%
ETR State + Local (pp)↓-6.1pts
0.1%
ETR Foreign Differential (pp)
—
Operating Lease Cost↑+0.0% +$0
$19K
Revenue YoY Variation↓-25.9pts
-100.0%
Income YoY Variation↑+146.9pts
37.6%
Revenue QoQ Variation↑+8122.9pts
8236.0%
Income QoQ Variation↓-23.8pts
-27.1%